Eric Lefkofsky is co-founder and CEO of Tempus, Inc. Tempus is a leading technology company which seeks to organize a genomic database of cancer. Doctos will compare this database to an individual patient’s DNA and then personalize individual treatments. This new method would allow patients with cancer to live a longer life. In fact, it has been found that up to 40% of patients who have had sequencing also have an improved life expectancy. Top cancer researchers are sequencing patients’ DNA and looking for patterns but it is hard to analyze the massive amounts of data that result. Tempus hopes to sequence nearly 20,000 patients in the near future. It has developed software that allows doctors to compare the patients genomic profile to a database.
Doctors can then determine the most effective treatments available to patients. In addition, Tempus has a partnership with Northwestern’s Lurie Comprehensive Cancer Center to give doctors at Northwestern the software necessary to analyze the sequencing data. The company has launched a new mobile app which will enable physicians to securely access patient information whenever they like. The app brings the advantages of the technology to physicians as they treat patients because physicians can access a patient’s report, get structured clinical information and a list of potential therapies whenever they want to access that information. Tempus has also come up with an innovative Tempus xF technology which is a liquid biopsy assay that can analyze 77 genes. Doctors can use xF to find resistance mutations. The assay can be used to determine the patient’s treatment plan and evaluate how effective it is. The company has also expanded its research into lung cancer by collaborating with Mary Crowley Cancer Research. The company has raised 320 million dollars in funding since it launched in 2015.
In addition to being a technology executive, Lefkofsky is the head of the Lefkofsky Family Foundation.
Learn More: adrinkwith.com/eric-lefkofsky/